Dried culture spots (DCS) of inactivated Mycobacteria strains designed as part of an external quality assessment (EQA) program for the GeneXpert system has applications to other molecular tuberculosis (TB) diagnostic platforms. DCS tested on the GenoType MTBDRplus and Mycobacterium CM assays performed well with MTBDRplus version 2 but require increased bacterial concentration for use with version 1. Q uality assurance (QA) refers to an umbrella of quality checks within a medical laboratory encompassing the entire testing process from specimen collection to result reporting (i.e., preanalytical, analytical, and postanalytical steps) to ensure high-quality testing (1). External quality assessment (EQA), sometimes referred to as proficiency testing, is just one component of a QA program and is defined as a system for objectively checking the performance of a laboratory using an external agency or facility (2). This is often challenging and costly for tuberculosis (TB) laboratories but is particularly exacerbated in low-resource settings (3), which may not always be equipped with an adequate level of biosafety to receive live Mycobacterium tuberculosis (MTB) cultures, and stringent requirements for transportation of such materials exist (4). Several TB EQA molecular schemes exist (http: //www.cap.org; 5, 6), but some provide the EQA material in a format containing preextracted DNA, making them inappropriate for the monitoring of the entire testing process from extraction to detection.
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To address the complexities of ongoing molecular diagnostic EQA systems in TB laboratories, a verification (fit-for-purpose) (7) and EQA program (pre-/postanalytics) (8) consisting of dried culture spot (DCS) material was developed for the molecular GeneXpert instrument performing the Xpert MTB/ RIF assay (Cepheid, Sunnyvale, CA) (9) . The major advantage of this approach is that the DCS contain whole, inactivated, and quantitated mycobacterial strains that can be safely transported as one would transport documents by mail, without the requirement of cold-chain transport. The spots are easy to use and robust, with a minimum shelf life of 9 months confirmed to date (10) .
The DCS EQA program has been successfully implemented in 207 National Health Laboratory Service (NHLS) GeneXpert testing laboratories in South Africa and 82 non-NHLS sites in 21 countries. The Global Laboratory Initiative (GLI) (advisors to the World Health Organization) has also endorsed the DCS for verification of the GeneXpert instrument. As the DCS material is not platform specific, we determined the potential application of the GeneXpert DCS program for the molecular line probe assay This involved resuspending the DCS in a 50-ml Nunc tube containing 2 ml of phosphate-buffered saline (PBS) for 15 min, with intermittent vortexing. This was followed by manual extraction (for MTBDRplus version 1) or GenoLyse extraction (for MTBDRplus version 2) of the entire lysate, as per the manufacturer's instructions. The extracted material was then amplified and hybridized as per the standard manufacturer's protocol for versions 1 and 2. The species identifications of the negative results for the MTBDRplus version 2 (TUB band absent) were determined using the GenoType Mycobacterium CM assay (Hain Lifescience, Germany). Table 1 lists the observed findings for the initial research laboratory testing and Table 2 for the pilot site testing.
The species of all DCS that tested negative on version 2 of the LPA in the research laboratory (Table 1) were further identified with the GenoType Mycobacterium CM assay. Of the eight M. kansasii, M. intracellulare, and M. fortuitum spots tested, the species of 6 from each were successfully identified (18/24 [75%]).
The M. intracellulare DCS tested on LPA version 2 at two of the pilot sites (Table 2 ; n ϭ 3 per site) were also tested on the Mycobacterium CM assay, and the species of 5/6 (83%) were correctly identified. One DCS (17%) was incorrectly reported as M. avium.
Although partially successful in the initial laboratory testing phase, the two pilot sites performing version 1 failed to produce interpretable results. This was due to the low bacillary load on the DCS designed for detection at a minimum of 150 CFU/ml, which is the lower limit of detection of the Xpert MTB/RIF test (9) . Since the LPA version 1 is validated only for use with smear-positive specimens, which has a limit of detection of 10,000 bacteria/ml 3 (11) , it is feasible to accept that version 1 will not detect M. tuberculosis on the DCS below this lower limit.
The reverse is true for the use of DCS with the MTBDRplus version 2 assay, as all (80/80) DCS results from the research laboratory and 96% (23/24) of the pilot site results were correctly reported. Rifampin resistance was identified by an rpoB wild-type 7 (WT7) missing band and a mutant 2A (MUT2A) band present by the LPA, which corresponds to the Xpert MTB/RIF probe D mutant. One of the pilot sites detected an RIF-resistant DCS as having a WT7 band and MUT2A band present. This may have been due to incorrect interpretation or contamination, but the finding was not considered clinically relevant. Of the three sites (one research laboratory and 2 routine service laboratories) that performed Mycobacterium CM assay testing on the negative results by MTBDRplus version 2, only one incorrect species identification was reported, possibly due to a mislabeled laboratory specimen.
Overall, the DCS program appears to be suitable not only for the Xpert MTB/RIF assay but also for the MTBDRplus assay version 2, due to their similar sensitivities, and it provides measurements for the entire testing process (DNA extraction through result reporting), as opposed to just the amplification and hybridization steps on DNAprepared EQA materials. The added advantage of the DCS technology is the ability to transport inactivated tuberculosis-positive specimens at room temperature, thereby reducing the overall program costs. Even though the GenoType MTBDRplus version 1 assay has been discontinued in several countries (Hain Lifescience, South Africa [Pty], Ltd., personal communication), if laboratories wish to use the DCS with this version, an increased bacterial concentration will need to be spotted onto the paper card.
Currently, the result reporting of the GeneXpert MTB/RIF EQA DCS program is automated and managed remotely through TBGxMonitor for real-time turnaround of the results, but it could be expanded to provide a more automated result reporting for the MTBDRplus assays. Other M. tuberculosis strains could also be included in the DCS panels that are suitable for second-line drug resistance testing, such as those with the MTBDRsl assay (Hain Lifescience, GmbH, Nehren, Germany).
